Enterprise Products Partners (NYSE:EPD) delivers 6.5% cash-return rate ahead of earnings report

Enterprise Products Partners (NYSE:EPD) delivers 6.5% cash-return rate ahead of earnings report

NEW YORK, July 18, 2026, 11:20 (EDT)

Enterprise Products Partners’ distribution and first-half buybacks correspond to an initial annualized cash-return rate of 6.53%. U.S. markets did not open on Saturday.

The projection takes on added significance following a 19.15% increase so far this year. The main distribution yield is currently 5.86%.

The calculation projects Enterprise’s $275 million in share buybacks for the first half of the year to an annual amount of $550 million, which is then compared with the company’s $82.65 billion market capitalization as of Friday.

The $2.24 yearly distribution represents a 5.86% yield based on a price of $38.20. Annualized share repurchases are projected to contribute an additional 0.67%.

Combined, these returns were 1.98 percentage points higher than the 10-year Treasury yield of 4.55% on Friday. That gap could attract income-focused investors.

The peer snapshot on Friday displays the distribution gap along with year-to-date price changes.

SecurityFriday closeFriday moveIndicated yield2026 YTD
Enterprise Products Partners $38.20increased 0.53%5.86%up 19.15%
Energy Transfer $20.32rose 0.59%6.64%advanced 23.23%
MPLX $57.06fell 0.19%7.55%up 6.91%
ONEOK $93.52improved 0.56%4.58%gained 27.24%

Enterprise’s base yield is lower than that of Energy Transfer and MPLX. Its projected buyback yield narrows most of the difference with Energy Transfer.

Enterprise units increased by 2.5% between July 10 and Friday. On Friday, they advanced 0.53%, as the S&P 500 dropped 1.01%.

Oil prices provided support as U.S. crude climbed 4.48% to $82.49. Energy was the sole advancing sector in the U.S. on Friday. The S&P 500 ended the week down 1.55%.

Enterprise increased its quarterly distribution by 2.8% to $0.56 per unit. The payment is scheduled for August 14 to unitholders on record as of July 31.

Operational distributable cash flow on a non-GAAP basis totaled $2.1 billion in the first quarter. The coverage ratio stood at 1.8 times, with retained cash flow amounting to $1.5 billion.

“This volume growth … resulted in a strong earnings and cash flow quarter,” co-CEO Jim Teague stated in April. Enterprise Products Partners L.P.

Pipeline transportation volumes increased 7% to 14.2 million barrels per day, while marine-terminal volumes were up 15% at 2.3 million barrels per day.

On Friday, Jefferies Financial Group analyst Julien Dumoulin-Smith reiterated a Hold rating on the stock with a $40 price target, suggesting an upside of 4.7% from Friday’s closing level.

Analysts continued to rate the stock Overweight, with a median price target at $42. Second-quarter earnings are projected at $0.75 per unit.

No Enterprise report is planned for next week. The partnership will announce second-quarter earnings before the market opens on July 30. Oil prices and Treasury yields continue to be the primary market drivers in the near term.

Risks persist. Share repurchases are optional, meaning the 6.53% projection might not hold. Reduced buyback activity or an increase in Treasury yields would compress the spread.

Roman Perkowski

Roman Perkowski is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Cracow University of Economics, he previously worked in investment research and corporate finance. His coverage helps readers understand the key forces driving global financial markets and emerging industries. Follow Roman Perkowski on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Constellation Energy

NASDAQ: CEG 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY

Walt Disney

NYSE: DIS 92 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 90 / 100
#5 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.
ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound
Previous Story

ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound

Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week
Next Story

Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week